探讨小儿特发性矮小症治疗中重组人生长激素应用的价值研究.docVIP

精品论文 参考文献 探讨小儿特发性矮小症治疗中重组人生长激素应用的价值研究 大庆油田总医院 163000 【摘 要】目的 浅析小儿特发性矮小症治疗中重组人生长激素应用的价值。方法 此次研究的对象是选择2012年11月—2013年12月收治的100例小儿特发性矮小症患者。将其临床资料进行回顾性分析，并随机的分为对照组和治疗组，对照组和治疗组各50例。对照组患者采取正常的营养治疗，并对患者补充钙和赖氨肌醇维生素B12。治疗组患者在对照组常规营养治疗的基础上采取重组人生长激素治疗，对比分析两组患者治疗前后生长速度、骨龄以及身高等情况。结果 治疗组治疗之后的生长速度为（13.2plusmn;2.4）cm/年，其差值明显高于对照组的（6.68plusmn;1.21）cm/年，对照组和治疗组患者治疗之后的生长速度、骨龄以及骨龄对应的身高标准差分值等进行比较，差异有统计学意义（Plt;0.05）。结论 小儿特发性矮小症治疗中重组人生长激素应用价值较高，不仅仅将患儿的生长速度增加，同时又是一种安全有效的治疗方法，有着一定的可行性和安全性，值得临床推广。 【关键词】小儿特发性矮小症；重组人生长激素；治疗；应用价值 [Abstract] Objective To analyze the value of recombinant human growth hormone in the treatment of children with idiopathic short stature.Methods the study was conducted in 100 children with idiopathic short stature who were treated in December 2013 November 2012.The clinical data were retrospectively analyzed，and randomly divided into control group and treatment group，control group and treatment group of 50 cases.Patients in the control group were treated with normal nutritional therapy，and the patients were treated with calcium and vitamin B12.Patients in the treatment group in the control group routine nutrition therapy based on recombinant human growth hormone therapy，comparison and analysis of velocity，bone age and height，and other biological of two groups of patients before and after treatment.Result in the treatment group，after the growth rate（13.2 + 2.4）cm / year.The difference was significantly higher than that of control group（6.68 + 1.21）/ years，control group and treatment group patients after the growth rate，bone age and bone age corresponds to the height standard deviation scores were compared，the difference has statistical significance（P lt; 0.05）.Conclusion children with idiopathic dwarfism in the treatment of recombinant human growth hormone has high application value，not only will increase the growth rate in children with，at the same time，it is a safe and effective method for the treatment of，has a certain feasibility and safety，is worth the clinical